Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 672

2.

The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.

Ziyadeh N, McAfee AT, Koro C, Landon J, Arnold Chan K.

Clin Ther. 2009 Nov;31(11):2665-77. doi: 10.1016/j.clinthera.2009.11.003.

PMID:
20110009
3.

Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.

Wang CC, Chen WL, Kao TW, Chang YW, Loh CH, Chou CC.

Clin Ther. 2011 Dec;33(12):1904-13. doi: 10.1016/j.clinthera.2011.10.025. Epub 2011 Nov 25. Erratum in: Clin Ther. 2012 Feb;34(2):508. Chou, Chih-Chieh [corrected to Chou, Chin-Chieh].

PMID:
22118894
4.

Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin.

Marceille JR, Goins JA, Soni R, Biery JC, Lee TA.

Pharmacotherapy. 2004 Oct;24(10):1317-22.

PMID:
15628829
5.

Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study.

Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS.

Diabetes Care. 2003 Nov;26(11):2983-9.

PMID:
14578227
6.
7.

Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study.

Hartung DM, Touchette DR, Bultemeier NC, Haxby DG.

Pharmacotherapy. 2005 Oct;25(10):1329-36.

PMID:
16185176
8.

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483.

PMID:
16861090
9.

Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes.

Toprani A, Fonseca V.

Diabetes Obes Metab. 2011 Mar;13(3):276-80. doi: 10.1111/j.1463-1326.2010.01348.x. Erratum in: Diabetes Obes Metab. 2012 Apr;14(4):386.

PMID:
21205120
11.

Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project.

Inzucchi SE, Masoudi FA, Wang Y, Kosiborod M, Foody JM, Setaro JF, Havranek EP, Krumholz HM.

Diabetes Care. 2005 Jul;28(7):1680-9.

PMID:
15983320
12.

Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.

Balkrishnan R, Arondekar BV, Camacho FT, Shenolikar RA, Horblyuk R, Anderson RT.

Clin Ther. 2007 Jun;29(6 Pt 1):1306-15.

PMID:
18036392
13.

Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy.

Panikar V, Chandalia HB, Joshi SR, Fafadia A, Santvana C.

J Assoc Physicians India. 2003 Nov;51:1061-4.

PMID:
15260389
14.

Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in medicaid-enrolled patients with type 2 diabetes mellitus.

Balkrishnan R, Arondekar BV, Camacho FT, Shenolikar RA, Horblyuk R, Anderson RT.

Clin Ther. 2007;29 Spec No:1306-15.

PMID:
18046930
15.

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Khanderia U, Pop-Busui R, Eagle KA.

Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Review.

PMID:
18698014
17.

Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years.

Grossman LD, Parlan G, Bailey AL, Yee G, Yu M, Chan JY.

Clin Ther. 2009 Jan;31(1):74-88. doi: 10.1016/j.clinthera.2009.01.004.

PMID:
19243708
18.

A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes.

Gerrits CM, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer S.

Pharmacoepidemiol Drug Saf. 2007 Oct;16(10):1065-71.

PMID:
17674425
19.

Pioglitazone initiation and subsequent hospitalization for congestive heart failure.

Karter AJ, Ahmed AT, Liu J, Moffet HH, Parker MM.

Diabet Med. 2005 Aug;22(8):986-93.

20.

The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.

Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS.

Acta Diabetol. 2009 Jun;46(2):145-54. doi: 10.1007/s00592-008-0090-3. Epub 2009 Feb 5.

PMID:
19194648

Supplemental Content

Support Center